Related references
Note: Only part of the references are listed.18F-DCFPyL PET Acquisition, Interpretation, and Reporting: Suggestions After Food and Drug Administration Approval
Hong Song et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review
Stephen McGeorge et al.
ADVANCES IN UROLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
68Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership
Giuseppe Carlucci et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Michael J. Morris et al.
CLINICAL CANCER RESEARCH (2021)
A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.
Jeremy C. Durack et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)
Kenneth J. Pienta et al.
JOURNAL OF UROLOGY (2021)
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE)
Mikael Anttinen et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review
Lars J. Petersen et al.
CANCER IMAGING (2020)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer
Thomas Horn et al.
EUROPEAN UROLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer
Bo Chen et al.
NUCLEAR MEDICINE COMMUNICATIONS (2019)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Update on 18F-Fluciclovine PET for Prostate Cancer Imaging
Ephraim E. Parent et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.
Andrew Loblaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion
Stephanie A Harmon et al.
Oncotarget (2018)
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
Marie Christine Hupe et al.
FRONTIERS IN ONCOLOGY (2018)
Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET
Louise Emmett et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort
Stacy Loeb et al.
EUROPEAN UROLOGY (2016)
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer
Mingfeng Zhang et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2013)
Management of Patients with Biochemical Recurrence After Local Therapy for Prostate Cancer
Channing J. Paller et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
Emmanuel S. Antonarakis et al.
BJU INTERNATIONAL (2012)
Dual Tracer 11C-Choline and FDG-PET in the Diagnosis of Biochemical Prostate Cancer Relapse After Radical Treatment
Jose A. Richter et al.
MOLECULAR IMAGING AND BIOLOGY (2010)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2007)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Share Paper
